文献速递糖尿病

循环修饰代谢物与1型糖尿病合并慢性肾脏病患者终末期肾病的风险

Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease.
PubMed 文献 · Diabetes Care · 2017-01-13

在Joslin肾脏研究前瞻性队列中,158例伴蛋白尿和慢性肾脏病3期的1型糖尿病患者随访中位11年,发现7种修饰代谢物(C-糖基色氨酸、假尿苷、O-磺基酪氨酸、N-乙酰苏氨酸、N-乙酰丝氨酸、N6-氨甲酰苏氨酰腺苷和N6-乙酰赖氨酸)血清水平与肾功能下降和至终末期肾病时间相关(P < 0.001),且独立于相关临床协变量。

要点

  • 在1型糖尿病伴蛋白尿和肾功能受损患者中,7种修饰代谢物血清水平升高与更快的肾功能下降相关,导致终末期肾病。
  • 这些代谢物的血清水平与肾功能下降和至终末期肾病时间相关(P < 0.001),独立于相关临床协变量。
  • 这些候选代谢物是终末期肾病的风险因素还是仅预后生物标志物尚待确定。

核心结论

  • 在基线伴有蛋白尿和肾功能受损的1型糖尿病患者中,循环某些修饰代谢物水平升高者经历更快的肾功能下降,导致终末期肾病。
  • 这些候选代谢物是1型糖尿病进展至终末期肾病的风险因素还是仅预后生物标志物尚待确定。

研究设计与样本

  • 研究为Joslin肾脏研究前瞻性队列,纳入158例伴蛋白尿和慢性肾脏病3期的1型糖尿病患者,随访中位11年。
  • 通过连续测量血清肌酐确定估算肾小球滤过率斜率,并确定至终末期肾病起始时间;基线血清样本进行全局代谢组学分析。

主要发现

  • 在至少80%的参与者中检测到110种氨基酸以及嘌呤和嘧啶代谢物。
  • 7种修饰代谢物(C-糖基色氨酸、假尿苷、O-磺基酪氨酸、N-乙酰苏氨酸、N-乙酰丝氨酸、N6-氨甲酰苏氨酰腺苷和N6-乙酰赖氨酸)的血清水平与肾功能下降和至终末期肾病时间相关(P < 0.001),独立于相关临床协变量。
  • 这些显著代谢物相互相关,并与肾小管损伤指标相关。

局限性

  • 这些候选代谢物是终末期肾病的风险因素还是仅预后生物标志物尚待确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with type 1 diabetes (T1D) with impaired renal function are at increased risk for end-stage renal disease (ESRD). Although the rate of progression varies, determinants and mechanisms of this variation are unknown. RESEARCH DESIGN AND METHODS: We examined serum metabolomic profiles associated with variation in renal function decline in participants with T1D (the Joslin Kidney Study prospective cohort). One hundred fifty-eight patients with proteinuria and chronic kidney disease stage 3 were followed for a median of 11 years to determine estimated glomerular filtration rate slopes from serial measurements of serum creatinine and to ascertain time to onset of ESRD. Baseline serum samples were subjected to global metabolomic profiling. RESULTS: One hundred ten amino acids and purine and pyrimidine metabolites were detected in at least 80% of participants. Serum levels of seven modified metabolites (C-glycosyltryptophan, pseudouridine, O-sulfotyrosine, N-acetylthreonine, N-acetylserine, N6-carbamoylthreonyladenosine, and N6-acetyllysine) were associated with renal function decline and time to ESRD (P < 0.001) independent of the relevant clinical covariates. The significant metabolites correlated with one another and with the indices of tubular injury. CONCLUSIONS: This prospective cohort study in participants with T1D, proteinuria, and impaired renal function at baseline demonstrated that patients with increased circulating levels of certain modified metabolites experience faster renal function decline, leading to ESRD. Whether some of these candidate metabolites are risk factors or just prognostic biomarkers of progression to ESRD in T1D needs to be determined.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Niewczas MA, Mathew AV, Croall S, et al. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Care. 2017. PMID: 28087576. doi:10.2337/dc16-0173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。